This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.


February 21, 2015
Indications for postoperative radiation therapy (PORT) for resected lung cancer are unclear.  This study evaluated outcomes from the National Cancer Data Base 2004-2006, including 2115 patients resected with pathologic N2 NSCLC, of whom  918 (43%) received PORT.  PORT was associated with better median survival (42 vs 38 mos, p=0.048) and was associat
February 21, 2015
SEER outcomes from 1973-2010 were evaluated, including a total of over 947,000 pts, of whom only 441 had atypical carcinoid tumors of the lung.  69% were women and 87% were white.  20% had stage IV disease at diagnosis.  78% of the patients underwent resection.  3-year survival was 85% for N0, 69% for N1-2, and 26% for stage IV.
February 16, 2015
This video shows a very rare vascular injury occurring during VATS left upper lobectomy, and its repair. The case suggests some of the limitations of VATS procedures.
February 16, 2015
Usually patients with prior cancer are excluded in lung cancer trials, but the impact on survival in lung cancer is not known. In a cohort of 102929 patients older than 65 with stage IV lung cancer, a propensity score analysis were performed and found that patients with prior cancer had better survival (all-cause and lung cancer-specific).
February 16, 2015
This trial randomized 61 pts to a program of endurance and strength training or no training beginning 5-7 weeks after lung resection for cancer and lasting 20 weeks.  Compared to controls, treatment group patients demonstrated significant improvements in peak O2 uptake, DLCO, leg and arm strength, muscle mass, and QOL.
February 13, 2015
This carefully prepared book is a wonderful compendium of scientific evidence regarding squamous cell cancer of the esophagus, written from a Japanese perspective.
February 6, 2015
The Centers for Medicare and Medicaid Services (CMS) announced on February 5, 2015, that CT lung cancer screening will be a covered service.  This long awaited decision followed the preliminary announcement in November 2014.  After a period of comment, the coverage ages were expanded to include patients 55-77 years old.  The process mandates maintena
February 3, 2015
This consensus statement from the European Neuroendocrine Society is based on extensive bibliographic searches and systematic review.  Surgery is the mainstay of therapy for most tumors, and includes resection of metastases when this can be accomplished in a curative manner.  Somatostatin analogues are considered first line therapy for unresectable c
February 2, 2015
The authors queried the National Cancer Data Base to assess outcomes of patients with R1 resection margins related to the presence and type of postoperative adjuvant therapy.  3.1% of over 54,000 resections had R1 margins, which negatively affected long-term survival.  Combined chemotherapy and radiation therapy improved outcomes; administration of c
February 2, 2015
This study propensity-score matched patients from a cohort who underwent resection for stage I or II lung cancer and compared 175 pairs who underwent VATS or open lobectomy.  The VATS group experienced shorter hospital length of stay, fewer complications, and more frequent discharge to home.  Survival was similar.